Corteva (CTVA) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
15 Jan, 2026Executive summary
Third quarter 2024 results were in line with expectations, with net sales down 10% year-over-year to $2.33B, reflecting challenging dynamics in Latin America and competitive pricing pressures.
Operating loss was reported for Q3, but strong execution led to over $400M in controllable cost savings for the year.
Seed business showed robust performance in North America with pricing and share gains, while Crop Protection delivered margin growth and benefited from demand for differentiated technology.
Full-year 2024 guidance was updated to reflect lower revenue expectations due to Latin America headwinds, but margin stability was supported by cost improvements and operational execution.
Preliminary 2025 outlook anticipates double-digit operating EBITDA growth and margin expansion, driven by new product gains, cost deflation, and continued investment in innovation.
Financial highlights
Q3 2024 net sales declined 10% year-over-year to $2.33B; YTD net sales down 4% to $12.9B.
Q3 2024 operating EBITDA was $(100)M, with a margin of (4.3)%; YTD operating EBITDA was $2.85B, down 5%, with a 22% margin.
Q3 2024 GAAP loss from continuing operations was $519M; YTD net income from continuing operations was $913M, down 22%.
Q3 2024 diluted loss per share was $(0.76); YTD diluted EPS was $1.29, down 21%.
Q3 2024 cost of goods sold was $1,565M, down from $1,646M in Q3 2023, mainly due to favorable currency, cost actions, and raw material deflation.
Outlook and guidance
Full-year 2024 net sales expected at $17.0–$17.2B, down 1% at midpoint; operating EBITDA forecasted at $3.35–$3.45B, up 1% at midpoint.
Operating EPS expected in the range of $2.50–$2.60, down 5% at midpoint.
Free cash flow guidance reaffirmed at $1.5–$2.0B; cash from operations projected at $2.1B–$2.6B.
2025 preliminary outlook: net sales $17.3–$17.7B, operating EBITDA $3.6–$4.0B, with double-digit EBITDA growth and margin expansion.
$400M cost improvements expected in 2025, driven by lower commodity costs, deflation, and productivity.
Latest events from Corteva
- Annual meeting to vote on directors, executive pay, and auditor ratification, all board-backed.CTVA
Proxy filing19 Mar 2026 - 2025 results delivered margin growth, strong governance, and pay aligned to performance and ESG.CTVA
Proxy filing19 Mar 2026 - Strong 2025 results and resilient nitrogen markets drive growth amid global and policy shifts.CTVA
Bank of America 2026 Global Agriculture and Materials Conference25 Feb 2026 - 2025 saw record margins, cash flow, and Bayer deal; 2026 set for further growth and separation.CTVA
Q4 20254 Feb 2026 - Seed strength and margin gains offset Crop Protection headwinds; 2024 outlook trimmed.CTVA
Q2 20242 Feb 2026 - 2024 guidance reaffirmed as cost savings, innovation, and strong seed performance drive long-term growth.CTVA
Wells Fargo 2024 Industrials Conference1 Feb 2026 - Seed growth, cost control, and innovation drive outlook despite Argentina and weather headwinds.CTVA
BMO Ag-Apalooza Conference20 Jan 2026 - Record 2024 margins and cash flow; 2025 targets 10% EBITDA growth and $1B buybacks.CTVA
Q4 20248 Jan 2026 - Q1 2025 operating EBITDA up 15% to $1.19B with margin gains; $1B buyback planned.CTVA
Q1 20258 Jan 2026